AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03522480 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Jamboxx Respiratory Therapy Device
Description: The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
Study NCT03522480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jamboxx Respiratory Therapy Device
Description: The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
Study NCT03522480 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autogenic Draining Training
Description: A respiratory therapist will teach children how to conduct the autogenic draining technique (a series of exhalations and inhalations) by demonstrating the technique to them, and having them practice in their office. Children will also receive an informational packet and short video about the technique for reference
Study NCT03174912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical BCG instillation
Description: ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer
Study NCT02742636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.
Study NCT02742636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.
Study NCT03333239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychodynamic psychotherapy
Description: the intervention follows the published in german manual: Psychoanalytische Behandlung von Kindern und Jugendlichen mit Angststörungen und Depressionen: Behandlungsmanual (Baumeister-Duru, Hofmann, Timmermann \& Wulf, 2013)
Study NCT03333239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral psychotherapy
Description: the interventions follow the published in german manuals: Depression (Ihle, Groen, Walter, Esser, \& Petermann, 2012) and Soziale Ängste und Leistungsängste (Büch, Döpfner, \& Petermann, 2015)
Study NCT03333239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychodynamic family intervention
Description: the intervention follows an adapted version of the manual: Chimp´s - Children of mentally ill parents (Wiegand-Gefe, Halverscheid, \& Plass, 2011)
Study NCT02279069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4-roll canne
Study NCT02279069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-roll canne
Study NCT02601664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Intervention
Description: pre-PCI intracoronary vasodilator administration and glycoprotein IIb/IIIa inhibitor administration, use of an embolization protection device if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
Study NCT02601664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PCI
Description: Conventional PCI
Study NCT02070588 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
Study NCT02070588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
Study NCT01197859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Definitive Contact Lens
Description: Daily wear contact lens
Study NCT01197859 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Biofinity
Description: Daily wear contact lens
Study NCT02550717 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Low-dose ASA for secondary prevention of cardiovascular events
Study NCT02550717 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs
Description: Secondary prevention of cardiovascular events
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, 130 mg/m2
Description: day1every three weeks (optional)
Study NCT02876432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes
Study NCT02876432 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes
Study NCT02876432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Description: 100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
Study NCT02876432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham electroacupuncture
Description: The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
Study NCT02876432 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
Study NCT01599637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGE025
Description: Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
Study NCT01599637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
Study NCT01602562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VACV tablets (Adults or pediatrics) or granules (pediatrics)
Description: A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
Study NCT02825862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Question-behaviour effect (for affective attitudes)
Description: Investigators propose to investigate the Question-behaviour effect (omit affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on affective attitudes will substituted for non-affective items (e.g. on political parties).
Study NCT02825862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Question-behaviour effect (negatively-worded attitudes)
Description: Behavioral: Question-behaviour effect (for negatively-worded attitudes) Investigators propose to investigate the Question-behaviour effect (omit negatively-worded affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on negatively-worded affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on negatively-worded affective attitudes will substituted for non-affective items (e.g. on political parties).
Study NCT02849717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise for Cancer Patients
Description: a standardized, daily, home-based, progressive exercise program
Study NCT01690598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
Study NCT01690598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
Study NCT02731053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blues program
Description: Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
Study NCT02558504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oesophagectomy
Study NCT02558504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Study NCT00700973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Violence Prevention Intervention
Description: This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.
Study NCT00700973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Substance use disorder usual care
Study NCT00837798 — intervention group
Intervention type: DEVICE
Intervention: CRM Device
Description: Pacemaker, ICD, or CRT device
Study NCT01959334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon (NG)
Study NCT01959334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon IM
Study NCT01424904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DGB-01 Supplementation
Description: Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.~Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.
Study NCT03109145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menopause educational secure messaging
Description: Participants read educational material about menopause and treatment option for menopause symptoms once a week using secure messaging on a electronic patient portal.
Study NCT03520946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg iv over 60 min on d1+15, q4w
Study NCT03520946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: 35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
Study NCT03520946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS 102
Description: 35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
Study NCT03887390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Medication Choice
Description: The Depression Medication Choice tool is a series of cards emphasizing issues that are important for the patient and the health care professional when choosing antidepressants: weight change, sexual issues, sleep, cost, side effects, and stopping approach. The Depression Medication Choice tool uses clear language and is designed to improve the understanding of patients regarding the different attributes of antidepressants, and for use during clinical encounters.
Study NCT00411684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDB-2914
Study NCT01040910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: smoking of cannabis
Description: smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
Study NCT01040910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: smoking cigarettes with placebo
Description: smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
Study NCT02261935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Existing home care nursing practice
Description: Home care nurses in this comparator group will provide care as per usual to their patients and family caregivers. The family is seen as the unit of care but no formal assessment of the caregiver will be done.
Study NCT02261935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice support tool intervention
Description: The intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~The completed CSNAT tool will be kept in the patient chart and will be integrated into the care provided by the nurse.~Update - December 22, 2016 - In some offices only, the CSNAT will be administered by a separate study nurse. Findings will be communicated to the home care nurse to inform the documenting, monitoring and addressing of family caregiver support needs.
Study NCT02529072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
Study NCT01007448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
Study NCT04496492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: Tocotrienol 200 mg orally twice a day
Study NCT02529072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC
Description: DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
Study NCT02171416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rilonacept
Study NCT02171416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00831337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL3
Description: 2 times daily 450 billion live bacteria (in each saschet)
Study NCT02743156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Description: intravascular ultrasound-guided percutaneous coronary intervention
Study NCT02743156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
Study NCT01335087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
Study NCT01335087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
Study NCT01335087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
Study NCT04479631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196
Description: BRII-196 given intravenously
Study NCT04479631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously
Study NCT04236115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine 4%
Description: Articaine 4% is dental local anaesthetic agent
Study NCT04236115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocain 3%
Description: prilocaine is dental local anaesthetic agent
Study NCT04236115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenalin
Description: adrenaline is a vasoconstrictor
Study NCT04236115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felypressin
Description: Felypressin is a vasoconstrictor
Study NCT02932007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate
Description: Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
Study NCT02684253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02684253 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Study NCT02309255 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT03733639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tisseel
Description: Reinforcement of esophagojejunal anastomoses after total gastrectomy with the product.
Study NCT03733639 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: No Tisseel
Description: No reinforcement of esophagojejunal anastomoses after total gastrectomy
Study NCT00479492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-866,087
Description: 1 mg of CP-866,087, administered QD for 84 days
Study NCT00479492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-866,087
Description: 5 mg of CP-866,087, administered QD for 84 days
Study NCT00479492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-866,087
Description: 10 mg of CP-866,087, administered QD for 84 days
Study NCT00479492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered QD for 84 days